Effect of Oral Magnesium Supplementation on Phosphate Level and Kidney Function in Children with Hyperphosphatemia: A Randomized Double-Blinded Placebo-Controlled Clinical Trial

Recruiting

• Conditions: hyperphosphatemiadecreased kidney function; hyperphosphatemia; kidney function; acute kidney injury; chronic kidney disease; phosphate; magnesium; glomerular filtration rate

• Registration Number: TCTR20220708002
• Lead Sponsor: Dr Soetomo General Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-08
• Study Completion: 2022-10-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

phosphate level above 6.51 mg/dL (age 2-5 years old); above 5.8 mg/dL (age 6-12 years old); or above 4.6 mg/dL (age 13-18 years old)

Exclusion Criteria

1. currently on hemodialysis or peritoneal dialysis
2. estimated glomerular filtration rate less than 15 ml/min/1.73 m2
3. serum magnesium level above 2.5 mg/dL
4. allergic to magnesium supplementation
5. history of severe gastrointestinal disease

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
estimated glomerular filtration rate after 1 month, 2 months, and 3 months of intervention 1.serum creatinine analyzed using Siemens Dimension Exl 200; 2.calculate eGFR (k x height in cm/serum Cr) k : 0.55 in 2-13 years old child and girl above 13 years old. k : 0.7 in boy 13-18 years old,serum phosphate level after 1 month, 2 months, and 3 months of intervention inorganic phosphate in serum analyzed using Siemens Dimension Exl 200

Secondary Outcome Measures

Name	Time	Method
serum magnesium level after 1 month, 2 months, and 3 months of intervention magnesium in serum analyzed using Siemens Dimension Exl 200,adverse event during intervention interview and physical examination